Någård, Mats http://orcid.org/0000-0001-9643-1638
Ah-See, Mei-Lin
Strauss, James
Wise-Draper, Trisha
Safran, Howard P.
Nadeau, Laura
Edenfield, William J.
Lewis, Lionel D.
Rekić, Dinko
Dota, Corina
Ottesen, Lone H.
Li, Yan
Mugundu, Ganesh M.
Funding for this research was provided by:
AstraZeneca
Article History
Received: 13 March 2023
Accepted: 12 June 2023
First Online: 27 June 2023
Declarations
:
: LDL is a consultant to G1 Therapeutics and 7 Hills Pharma LLC. He also received, through an award to his institution, clinical trial funding for this study from AstraZeneca and other similar clinical trial funding support from the following sponsors: Bristol Myers Squibb, Bayer Pharmaceuticals, and AbbVie. WJE is a consultant for Chimerix Corp. CD, DR, MA, and MN are employees and shareholders of AstraZeneca. LHO was an employee of AstraZeneca at the time of conduct and reporting of this study. LHO is also a shareholder of AstraZeneca. All other authors have declared no conflicts of interest.
: This study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, applicable local regulatory requirements, and the AstraZeneca policy on bioethics [CitationRef removed].
: The institutional review boards or independent ethics committees of all investigational sites approved the protocol, and all patients provided written, informed consent.